RNAi Therapeutics Market Share, Size, and Outlook by 2031
RNAi Therapeutics Market: Size and Share
-
CAGR (2023 - 2031)16.5% -
Market Size 2021
US$ 1.5 Billion -
Market Size 2031
US$ 3.2 Billion
Market Dynamics
- RNAi Therapeutics in Cancer Therapy
- Rising Research & Development (R&D) activity
- Imaging Modalities for RNAi Therapeutics for RNAi Therapeutics
Market Segmentation
Molecule Type - Small Interfering RNAs
- MicroRNA
Application - Genetic Disorders
- Oncology
- Neurodegenerative Disorders
- Cardiovascular
- Respiratory Disorders
- Infectious Diseases
- Renal Diseases
Route of Administration - Intradermal Injections
- Pulmonary Delivery
- Intravenous Injections
- Intraperitoneal Injections
End User - Diagnostic Laboratories
- Research & Academic Laboratories
- Hospitals
RNAi Therapeutics Market Players Density: Understanding Its Impact on Business Dynamics
The RNAi Therapeutics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the RNAi Therapeutics Market are:
- Alnylam Pharmaceuticals, Inc.,
- Sanofi,
- Olix Pharmaceuticals, Inc.,
- GlaxoSmithKline Plc,
- Benitec Biopharma,
- Arbutus Biopharma Corporation,
Disclaimer: The companies listed above are not ranked in any particular order.
- Get the RNAi Therapeutics Market top key players overview
Get Free Sample For